Knowledge Tree
cardiovascular events
Also known as: cardiac events
Facts (20)
Sources
EBM Tools for Practice: Best Biomarkers for Inflammation lipid.org 12 facts
measurementIn the Canakinumab Anti-inflammatory Thrombosis Outcome Trial (CANTOS), lowering high-sensitivity C-reactive protein (hs-CRP) below 2 mg/L resulted in a 25% reduction in major adverse cardiovascular events (p<0.001) and a 31% reduction in cardiovascular mortality (p<0.0001), despite no change in low-density lipoprotein cholesterol (LDL-C).
claimThe Safety and Cardiovascular Event Efficacy of Bococizumab in High-Risk Patients (SPIRES) Trial showed that persistent elevation of high-sensitivity C-reactive protein (hs-CRP) at 14 weeks was associated with increased future cardiovascular events, even after low levels of low-density lipoprotein cholesterol (LDL-C) were achieved.
claimIn the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) trial, the baseline level of high-sensitivity C-reactive protein (hs-CRP) predicted which patients were at the greatest risk for cardiovascular events.
claimIn the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER), patients experienced the fewest cardiovascular events when achieving both a low-density lipoprotein cholesterol (LDL-C) <70 mg/dL and a high-sensitivity C-reactive protein (hs-CRP) <2 mg/L.
claimIn a direct comparison of a panel of inflammatory markers (including serum amyloid A, IL-6, and soluble intercellular adhesion molecule type 1 [sICAM-1]) and various lipid markers, high-sensitivity C-reactive protein (hs-CRP) surpassed all of them as a predictor of cardiovascular events.
claimElevated levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) are predictive for cardiovascular events in primary prevention and are associated with approximately a doubling of risk.
claimIn the Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY) and the Stabilization of Plaques using Darapladib — Thrombosis in Myocardial Infarction 52 (SOLID-TIMI 52) trial, interleukin-6 (IL-6) was significantly and independently associated with incident cardiovascular events, including cardiovascular death, myocardial infarction, and heart failure.
claimElevated levels of high-sensitivity C-reactive protein (hs-CRP) among healthy individuals is a strong predictor of future cardiovascular events, with a two to four-fold increase in risk comparing the top versus bottom tertile, independently of age, gender, and cholesterol levels.
claimPharmacologic inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) does not reduce cardiovascular event rates, and therefore Lp-PLA2 is not a goal of therapy, nor is it an FDA-approved or health insurance-reimbursed test.
claimProspective studies have shown an association between elevated myeloperoxidase (MPO) levels and future cardiovascular event risk in healthy individuals and patients with stable and unstable coronary artery disease (CAD), though other studies have found MPO to be less predictive.
claimIn the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), baseline levels of C-reactive protein (CRP) and low-density lipoprotein cholesterol (LDL-C) were comparable in identifying patient subsets at risk of future cardiovascular events.
claimTherapies with anti-inflammatory effects in patients with an increased inflammatory status can reduce cardiovascular events, as demonstrated by the CANTOS study.
Chronic Inflammation - StatPearls - NCBI Bookshelf ncbi.nlm.nih.gov 2 facts
claimStatins have anti-inflammatory effects by reducing multiple circulating and cellular biomediators of inflammation, which contributes to the reduction in cardiovascular events.
claimAtherosclerosis is a pro-inflammatory state characterized by chronic low-grade inflammation that increases the risk of cardiovascular events such as myocardial infarction and stroke.
Chronic Inflammation: How to Test For it and Prevent it medichecks.com Jan 31, 2024 1 fact
referenceThe National Center for Biotechnology Information (NCBI) published 'Smoking and inflammation: the cause and consequences of inflammation' in the American Journal of Physiology in 2005, which notes that smoking triggers an immunologic response and that inflammatory markers predict future cardiovascular events.
A Consensus Proposal for Nutritional Indicators to Assess ... - Frontiers frontiersin.org 1 fact
procedureThe 'Diet-Related Morbidity/Mortality Statistics' indicator monitors the occurrence of cardiovascular events, type II diabetes, dyslipidemia, hypertension, osteoporosis, neurodegenerative diseases, and certain cancers as a proxy for the consumption of healthy diets.
Tracking Inflammation Through Biomarkers rupahealth.com Jul 24, 2024 1 fact
claimElevated high-sensitivity C-reactive protein (hs-CRP) levels indicate inflammation associated with atherosclerosis and increased cardiovascular risk, which prompts early intervention to reduce the risk of future adverse cardiac events.
The lunar cycle: effects on human and animal behavior and physiology pubmed.ncbi.nlm.nih.gov 1 fact
claimHospital and emergency unit admissions for cardiovascular events, acute coronary events, variceal hemorrhage, diarrhea, and urinary retention have been observed to correlate with moon phases.
Editorial: Inflammation and chronic disease - Frontiers frontiersin.org Jul 1, 2024 1 fact
referenceLow-grade inflammation serves as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes, as reported in a 2021 study in Cardiovascular Diabetology.
Origins and evolution of the Western diet: health implications for the ... academia.edu 1 fact
referenceRidker PM, Rifai N, Rose L, Buring JE, and Cook NR compared the predictive value of C-reactive protein and low-density lipoprotein cholesterol levels for first cardiovascular events in a 2002 study published in the New England Journal of Medicine.